Thank you very much and welcome, everyone, to today's conference. Today we will first look into our performance in the third quarter and then also reflect a bit on the current market situation and our expectations for the remainder of 2025. So we can move over to page number two, please.
So if we start by looking at the development of some of our long-term, more strategic KPIs, we can see that we continue to clearly track in line with our plan to increase the share of sales from recurring revenue products and also accelerate the share of sales from high-margin products like our Paragon offering or portfolio consumables in infection prevention and beta bags in sterile transfer. This is all supported by solid and effective quality processes as well.
Sales from recurring revenue are now at 65%, and high margin products make up more than two-thirds of sales today.
When it comes to quality, the number of field actions in relation to sales has decreased significantly, and we see this positive trend continuing. Also in the third quarter of this year, these improvements should, of course, be achieved through responsible leverage and an attractive long-term return on invested capital. We can move then to page number three please.
So if we focus then on the third quarter for a moment and the key takeaways for the quarter, we can see that we demonstrated strength with significant growth in the topline. Net sales grew by 9.5% organically, with positive development in all business areas and all regions. Order intake also increased by 4.7% organically. Adjusted gross and EBITDA margins improved, mainly due to acquisitions. Healthy price increases, positive mix, and productivity gains. And this is in spite of continued strong headwinds from tariffs and currency impacts on the EBITA margin, which signals that the underlying development is even stronger. Our financial position remains solid, with our financial leverage well below two and a half times EBITA. We can then move over to page number four, please.
So taking a step back then and looking at some of the key activities and events in the third quarter when it comes to our offering and customers, I'm happy to see that Sweden’s first fully automated, centralized sterile supply department at the Malmö University Hospital has been inaugurated, with Getinge’s T-DOC providing the intelligence that optimizes sterile supply management by enhancing quality, patient safety, cost efficiency, and also improving the work environment.
T-DOC is really the critical enabler for successful operations, and this is something that we've seen for over 25 years now with this product. Productivity is a key priority for us.
By implementing the Getinge Manufacturing Excellence Program, we've been able to cut lead times by more than 20% and also reduce the COGS by about 10% for some of our key products in the product category, which includes washers, isolators, and sterilizers.
We've also joined forces with Philips to offer hospitals in key markets an integrated anesthesia workstation for the operating room.
So this new solution unites precise anesthesia delivery and state-of-the-art patient monitoring technologies. Thank you very much and welcome, everyone, to today's conference. When it comes to sustainability and quality.
In the quarter, we regained the CE Mark for our Cardiosave Intra-Aortic Balloon Pump. This is, of course, subject to certain conditions, and we plan to gradually resume deliveries towards the end of this year. Regarding our implants business, we received EU MDR approval for three additional indications for our V12 balloon expandable covered stents.
And this will now strengthen our position.
It's a critical enabler for success in the European endovascular market regarding our operations. Key Performance Indicators (KPIs).
I'm happy to see that our CO2 emissions from operations continue to decrease. Let's move then to page number five and look at our top line performance in a bit more detail.
Overall, we had a particularly strong top-line performance in acute care therapies and life sciences.
Our order intake grew 4.7% organically, and the organic order intake for acute care therapies increased, mainly due to ventilators in critical care and ECLS consumables. Life Science showed double-digit growth in the organic order intake for the quarter due to very strong performance in style transfer, and the organic order intake for surgical workflows declined a bit in the quarter. Despite the strong trend that we've seen for operating tables and also consumables in infection control.
When it comes to sales, we grew 9.5% organically. Both acute care therapies and life science saw double-digit growth in organic net sales. This was mainly due to the very strong performance in ventilator ECLS therapy and also within cardiac surgery. Organic net sales for life science primarily increased as a result of healthy growth in sterile transfer and also capital goods in the washer, isolator, and sterilizer category within surgical workflows.
Organic net sales increased due to growth in infection control and also thanks to operating tables within surgical workflows.
We can then move over to page number six and I'll hand over to you Agneta.